BiomX’s (PHGE) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of BiomX (NYSEMKT:PHGE) in a research note issued to investors on Monday, Benzinga reports. They currently have a $2.00 price target on the stock.

BiomX Trading Up 1.8 %

NYSEMKT PHGE opened at $0.30 on Monday. The business’s fifty day simple moving average is $0.32 and its two-hundred day simple moving average is $0.31. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.51. The stock has a market cap of $16.30 million, a PE ratio of -0.56 and a beta of 1.36.

About BiomX

BiomX Inc, a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC).